GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » WuXi Biologics (Cayman) Inc (MEX:2269) » Definitions » Capital Expenditure

WuXi Biologics (Cayman) (MEX:2269) Capital Expenditure : MXN-10,622.97 Mil (TTM As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is WuXi Biologics (Cayman) Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

WuXi Biologics (Cayman)'s cash flow for capital expenditures for the six months ended in Dec. 2024 was MXN-5,907 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Dec. 2024 was MXN-10,622.97 Mil.

WuXi Biologics (Cayman) Capital Expenditure Historical Data

The historical data trend for WuXi Biologics (Cayman)'s Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WuXi Biologics (Cayman) Capital Expenditure Chart

WuXi Biologics (Cayman) Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Capital Expenditure
Get a 7-Day Free Trial Premium Member Only Premium Member Only -18,326.87 -21,009.40 -16,410.65 -10,057.11 -11,256.47

WuXi Biologics (Cayman) Semi-Annual Data
Dec14 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Capital Expenditure Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8,903.58 -6,115.88 -3,983.77 -4,715.66 -5,907.32

WuXi Biologics (Cayman) Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was MXN-10,622.97 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

WuXi Biologics (Cayman) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » WuXi Biologics (Cayman) Inc (MEX:2269) » Definitions » Capital Expenditure
Comparable Companies
HKSE:01177 HKSE:09926 HKSE:01801 HKSE:06990 HKSE:01530 HKSE:09995 HKSE:01877 HKSE:01548 HKSE:02696 HKSE:06855 VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:UCB XBRU:ARGX ONC XKRX:068270 BNTX
Traded in Other Exchanges
WXIBF:USA WXXWY:USA 02269:Hong Kong 1FW2:Germany
Address
No. 108, Meiliang Road, Mashan Binhu District, Wuxi, CHN, 214092
Website
https://www.wuxibiologics.com
WuXi Biologics is one of the largest global biologic global contract development and manufacturing organizations. WuXi Biologics, incorporated in 2014 following the reorganization of WuXi PharmaTech, later known as WuXi AppTec, now has global revenue of CNY 18.7 billion. North America represented 57.3% of total revenue in 2024. The firm has a "follow and win the molecule" strategy by providing end-to-end services, from drug discovery to commercial manufacturing. It also adopts a global dual sourcing strategy by providing drug products and drug substance manufacturing.

WuXi Biologics (Cayman) Headlines

No Headlines